^
    Back
    Association details:
    Biomarker:FGFR3-TACC3 fusion
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    JTO Clin Res Rep
    Title:

    Successful Treatment and Re-treatment with Erdafitinib for a Patient with FGFR3-TACC3 Fusion Squamous Non-Small Cell Lung Cancer: A Case Report

    Published date:
    03/29/2023
    Excerpt:
    ...we report a case of a patient with FGFR3-TACC3 fusion squamous NSCLC who achieved a radiographic response and disease control for 11 months upon initial treatment with erdafitinib and subsequently obtained an additional 8 months of disease control following erdafitinib re-treatment after 5 months of intervening chemotherapy.
    DOI:
    https://doi.org/10.1016/j.jtocrr.2023.100511